#Oculis,#NeuroOphthalmology,#ClinicalTrials,#PharmaNews To view or add a comment, sign in Durable 3-Year Vision Gains with MCO-010: A Transformative Step Toward Restoring Sight Were thrilled to announce positive three-year follow-up data from Nanoscope Therapeutics REMAIN study of MCO-010, showing sustained 3-line vision improvements at 152 weeks in patients with Retinitis Pigmentosa (RP)
Deformability Optimization: Integrating biocompatible edge activators to lower the elastic modulus of the membrane, enabling the vesicles to physically squeeze through the stratum corneum via intercellular pathways
Declarations Funding None to declare
Exposure to LPS during pregnancy gave rise to features that are relevant to HDP in rats offspring, which was prevented by treatment with the AT II receptor inhibitor losartan (242)
No correlations were observed with any of these variables (Supplementary Fig
Barcena E, Trinh V, McIntyre SE, Simien R, Cain S, Diab A, Amaria RN, Patel SP, Glitza IC, Tawbi HAH, Davies MA , Hwu WJ